1
EXHBIT 10.9
CONFIDENTIAL TREATMENT REQUEST
------------------------------
Confidential Portions Of This Agreement Which Have Been Redacted Are Marked
With Brackets ("[***]"). The Omitted Material Has Been Filed Separately With The
Securities And Exchange Commission.
HORIZON PHARMACEUTICAL & INPHARMAKON
COLLABORATION AGREEMENT
THIS AGREEMENT made as of the 31st day of October, 1998 ("Effective Date")
between Horizon Pharmaceutical Corporation, a Delaware corporation of 000
Xxxxxxx Xxxxxxx, Xxxxx 000, Xxxxxxx, Xxxxxxx 00000 ("Horizon") and InpharmaKon
Corporation, a Delaware corporation of 000 Xxxxxxxx Xxxx, Xxxxx 000, Xxxxxxxxxx,
Xxxxxxxx 00000 ("Inpharmakon").
Recitals:
---------
A. Horizon is a pharmaceutical product development and marketing company;
B. Inpharmakon is in the business of developing and assembling literature
based product registration packages for the purpose of enabling marketing
partners to file NDAs (defined below) with the FDA (defined below) for marketing
approval of off label indications for FDA approved pharmaceutical products.
C. Horizon wishes to collaborate with Inpharmakon and Inpharmakon wishes to
collaborate with Horizon for the purpose of preparing a NDA for submission by
Horizon to the FDA requesting approval to market [***] for the indicated use of
migraine prophylaxis on the following terms and conditions.
NOW, THEREFORE, the parties agree as follows:
ARTICLE I
Definitions
-----------
In this Agreement the following expressions shall have the meaning set
forth in this Article.
1.01 Accounting Period. The term "Accounting Period" means a calendar
quarter.
1.02 Affiliate. The term "Affiliate" means a corporation or business entity
which, directly or indirectly, is controlled by one of the parties or controls
one of the parties. For this purpose, the meaning of the word "control" shall
include, but not be limited to, ownership of fifty percent (50%) or more of the
voting shares or interest of such corporation or business entity.
1
2
[***] - CONFIDENTIAL TREATMENT REQUESTED
1.03 ANDA. The term "ANDA" means an Abbreviated New Drug Application.
1.04 Clinical Trials. The term "Clinical Trials" refers to the clinical
trials which Horizon is required to perform under Section 3.01 (ii) below.
1.05 Confidential Information. The term "Confidential Information" is
defined in Article VII below.
1.06 FDA. The term "FDA" means the United States Food and Drug
Administration.
1.07 First Commercial Sale. The term "First Commercial Sale" means the
first sale of the Product to a third party purchaser after NDA approval of the
Product for the Indication.
1.08 Formulation. The term "Formulation" is defined in Section 3.01(i)
below.
1.09 Horizon Affiliate. The term "Horizon Affiliate" means an Affiliate of
Horizon.
1.10 Indication. The term "Indication" means the indication for migraine
prophylaxis.
1.11 Inpharmakon Affiliate. The term "Inpharmakon Affiliate" means an
Affiliate of Inpharmakon.
1.12 NDA. The term "NDA" means a New Drug Application submitted to the
FDA requesting approval to market the Product for the Indication.
1.13 Net Sales. The term "Net Sales" means the gross invoice price of all
Product using the Formulation actually billed by Horizon, Horizon Affiliates or
sublicensees and their Affiliates to unrelated third party customers less (i)
any direct or indirect credits and allowances or adjustments granted to such
customers, including, without limitation, credits and allowances on account of
price adjustments or on account of rejection or return of Product previously
sold, (ii) any trade and cash discounts, and rebates, (iii) any sales, excise,
turnover and similar taxes, and any duties and other governmental charges
imposed upon the production, use or sale of Product or partly processed Product,
and (iv) transportation, insurance and other handling charges provided that such
charges can be reasonably allocated to such xxxxxxxx and are not separately
invoiced.
1.14 Opportunity Package. The term "Opportunity Package" means the
existing opportunity package already delivered to Horizon, receipt of which is
hereby acknowledged, which describes the Product, the targeted indication, and
an overview of its off label usage and was based upon a review of the published
clinical data for the Product and a patent search to establish prima facie
feasibility.
1.15 Product. The term "Product" means [***].
2
3
1.16 Sublicense. The term "Sublicense" is defined in Section 4.02 below.
ARTICLE II
Collaboration
-------------
2.01 Scope. Horizon shall work to obtain NDA registration for and
commercialization of the Product indicated for the Indication. Horizon shall
develop a once a day proprietary formulation for the Product and have primary
responsibility for clinical, formulation, manufacturing, and regulatory issues,
and preparation of the NDA for the Product for the Indication.
2.02. Opportunity Package. Inpharmakon shall give Horizon the exclusive
right to use the Opportunity Package for the purposes of preparing and filing a
NDA for the Product with the FDA for the Indication. Subject to Inpharmakon's
rights upon termination under Article IX below, with effect from the Effective
Date, Inpharmakon shall assert against Horizon no claim to the ownership of the
following intellectual property related to the Product (i) the Formulation
developed by or for Horizon under Section 3.01(i) below, or (ii) the data
arising from the Clinical Trials, nor to the rights to sales, marketing and
distribution for the Product for the Indication. After Horizon has contracted
with a formulator to develop the Formulation, Horizon shall have the right and
power to sublicense its exclusive rights to use the Opportunity Package.
2.03 Sublicenses. In the event Horizon enters into any Sublicenses,
Horizon shall provide Inpharmakon with a copy of each such Sublicense within 10
days of its execution.
ARTICLE III
Responsibilities of the Parties
-------------------------------
3.01. Responsibilities of Horizon. Horizon's responsibilities are as
follows:
i) To develop or have developed for it a workable once a day
formulation (the "Formulation") for the Product or, with
Inpharmakon's consent which consent will not be unreasonably
withheld, substitute another formulation (also referred to as the
"Formulation") with strong marketable differences over available
generic formulations of the Product;
ii) To conduct such clinical trials ("Clinical Trials") as may be
necessary to prepare and file a NDA for the Product using the
Formulation and indicated for the Indication; and
iii) To prepare and file with the FDA a NDA registration package for
the Product using the Formulation indicated for migraine
prophylaxis, and exert all reasonable efforts to obtain approval
of the NDA and commercialize the Product in the United States of
America.
3
4
3.02 License of Formulation. In the event Horizon licenses the Formulation
from a third party, Horizon shall ensure that the license permits Horizon to
assign its interest in the Formulation to Inpharmakon should Inpharmakon
exercise its rights to assume Horizon's rights to the Formulation under Sections
9.01 and 9.02 below.
3.03 Responsibilities of Inpharmakon: Inpharmakon's responsibilities are
to provide Horizon with the following services:
i) To deliver the Opportunity Package to Horizon plus, at no
additional cost to Horizon, provide additional review of such
published clinical trials not found in the Opportunity Package as
the FDA may require after its initial review of the NDA for the
Indication;
ii) To cooperate with and assist Horizon to design, conduct, and
evaluate the Clinical Trials using the Formulation for the
purpose of establishing safety and efficacy for the Product
indicated for the Indication;
iii) To cooperate with and assist Horizon to assemble the NDA for the
Product indicated for the Indication, including assembly of
published clinical literature and summaries;
iv) To assist and advise Horizon concerning follow-up information
required by the FDA in support of the NDA, including attendance
at meetings with the FDA; and
v) Provide other reasonable services as may be agreed by the parties
in support of Horizon's efforts to obtain approval of the NDA for
the Product for the Indication.
3.04 FDA Regulatory Support. In the event that Horizon requires support
with regard to its activities regulated by the FDA over and above Inpharmakon's
services under Section 3.03(ii) through iv) above, Inpharmakon or an Inpharmakon
Affiliate shall provide reasonable support requested by Horizon. Such support
shall be free of charge during the first 8 months of the term of this Agreement.
Thereafter Inpharmakon shall charge Horizon at the provider's (Inpharmakon's or
the Inpharmakon Affiliate's) regular rates presently $120 per hour and Horizon
shall pay such charges within 30 days of the invoice date.
3.05 Inpharmakon Expenses. Horizon shall reimburse Inpharmakon for
Inpharmakon's documented out of pocket travel expenses related to the
performance of its responsibilities under Section 3.03(ii) through (v) above.
Horizon shall make such reimbursements within 30 days of the invoice date.
4
5
[***] - CONFIDENTIAL TREATMENT REQUESTED
ARTICLE IV
Compensation
4.01 Fees and Royalties. Horizon shall pay to Inpharmakon as compensation
for its services:
i) $[***] within 30 days after the Effective Date;
ii) $[***] within 30 days after filing the NDA for the Product for
the Indication
iii) $[***] within 30 days after approval of such NDA; and
iv) A royalty of [***] of the Net Sales by Horizon or Horizon
Affiliates payable 45 days after the end of each Accounting
Period on all sales of the Product using the Formulation for so
long as Horizon or a Horizon Affiliate sell the Product.
Under no circumstances shall payments received by Inpharmakon under paragraphs
(i) through (iii) of this Section be refundable in whole or in part.
4.02 Sublicenses. In the event that Horizon grants any third party a
sublicense or other rights (together referred to as a "Sublicense") to make,
have made, use, import, market or sell the Product for the Indication, Horizon
shall pay to Inpharmakon the following royalties:
i) If a Sublicense is granted after Horizon enters into a contract
for development of the Formulation, 50% of the consideration
(cash and in kind) other than royalties under paragraph (v) of
this Section received by Horizon less costs incurred by Horizon
on behalf of the sublicensee and reimbursed by the sublicensee;
ii) If a Sublicense is granted after development of the Formulation
has been completed, 33% of the consideration (cash and in kind)
other than royalties under paragraph (v) of this Section received
by Horizon less costs incurred by Horizon on behalf of the
sublicensee and reimbursed by the sublicensee;
iii) If a Sublicense is granted after completion of the Clinical
Trials, 25% of the consideration (cash and in kind) other than
royalties under paragraph (v) of this Section received by Horizon
less costs incurred by Horizon on behalf of the sublicensee and
reimbursed by the sublicensee; or
iv) If a Sublicense is granted after approval of the NDA for the
Product indicated for the Indication, 20% of the consideration
(cash and in kind) other than royalties under paragraph (v) of
this Section received by Horizon less costs incurred by Horizon
on behalf of the sublicensee and reimbursed by the sublicensee;
and
5
6
[***] - CONFIDENTIAL TREATMENT REQUESTED
v) With effect from the First Commercial Sale, 5% of Net Sales by
sublicencees and their Affiliates.
4.03 No Release of Section 4.01 Payments. The grant of Sublicenses by
Horizon shall not release Horizon from its obligations to make the payments
required by Section 4.01(i) through (iii) above.
4.04 Other Indications. Provided that Horizon has paid all of the payments
required by Section 4.01(i) through (iii) above, Horizon shall have the right to
prepare and file ANDAs and NDAs for the Product for indications other than the
Indication. In that event the following provisions shall apply:
i) If Product sold by Horizon or Horizon Affiliates for such
indications use the Formulation, Horizon shall pay to Inpharmakon
the royalties as provided under Section 4.01(iv) above.
ii) If Product sold by Horizon or Horizon Affiliates for such
indications does not use the Formulation (i.e. it uses another
formulation useful in the therapeutic range for migraine
prophylaxis which improves on generically available formulations
for the Product) but the Product is prescribed for migraine
prophylaxis, Horizon shall pay to Inpharmakon the royalties as
provided under Section 4.01(iv) above on all such sales of the
Product for such prescriptions.
iii) Horizon shall pay to Inpharmakon the royalties provided under
Section 4.02(v) on all sales of Product by sublicensees and their
Affiliates which, if made by Horizon, would be subject to royalty
payments under paragraphs (i) or ii) of this Section.
iv) No royalties shall be due or payable on the Product for such
indications where the Product uses a formulation that is neither
useful in the therapeutic range of migraine prophylaxis nor a
formulation which improves on generically available formulations
for the Product, and the formulation is not prescribed for
migraine prophylaxis.
For the purposes of paragraphs (ii) and (iv) of this Section the term "improves"
refers to a technical or non-technical difference in the formulation not found
in generically available formulations for the Product which difference
differentiates the Product from other [***] products (using either the
Formulation or a generically available formulation) for marketing purposes.
6
7
ARTICLE V
Clinical Trials
---------------
For the purposes of Section 3.01(ii) above, Horizon shall contract with LAB
Biosyn of Montreal, Canada or another clinical research organization to perform
clinical trials the same as or equivalent to (1) the program prepared by LAB
Biosyn, a copy of which Inpharmakon shall provide to Horizon contemporaneously
with the execution of this Agreement, or (2) that recommended by the FDA.
ARTICLE VI
Payment of Royalties; Audit
---------------------------
6.01 Payment of Royalties. Horizon shall remit all royalty payments to
Inpharmakon no later than 45 days after the close of each Accounting Period.
Each royalty payment shall be accompanied by a report of the Net Sales subject
to royalty during the Accounting Period. Horizon will deduct withholding taxes
from payments to Inpharmakon only if required by applicable law.
6.02 Audit Rights. The following provisions shall apply:
(i) Inpharmakon, at its own expense, shall have the right, upon
reasonable prior notice, but no more than once in any year, to
appoint independent auditors and have them during normal business
hours, inspect and copy the books and accounts of Horizon,
Horizon Affiliates and Horizon's sublicensees, if any, related to
the payment and calculation of royalties arising under this
Agreement. Horizon shall cooperate and cause Horizon Affiliates
and sublicensees, if any, to cooperate with such auditors. The
auditors performing the audit shall disclose to Inpharmakon only
information relating to the accuracy of records kept and the
payments made, and shall be under a duty to keep confidential any
other information obtained from such records.
(ii) If any such audit establishes that Horizon has underpaid or
overpaid the amount due, Horizon shall promptly pay any remaining
amounts due as established by such audit or, in the event of an
overpayment, Inpharmakon shall promptly refund any such over
payment. If the underpayment is by 5% or more during any
Accounting Period, Horizon shall reimburse Inpharmakon for its
out of pocket expense of such audit, and shall pay to Inpharmakon
interest on the amount of the underpayment at a rate of 3% above
the official prime rate, as announced from time to time by
Citibank NA, New York, or at such lower rate as shall then be the
maximum rate permitted by law that may be charged on any such
overdue payment from the date due until paid.
7
8
ARTICLE VII
Confidentiality
For a period of 5 years after first disclosure, the parties shall keep
completely confidential, shall not publish or otherwise disclose, and shall not
use for any purpose other than the purposes contemplated by this Agreement, any
Confidential Information without the consent of the disclosing party first had
and obtained. The term "Confidential Information" is that information furnished
by either party to the other in writing and marked "Confidential", or if first
disclosed orally, disclosed in writing and marked "Confidential" within 30 days
after first disclosure. Confidential Information shall not include information
that the receiving party can establish by competent proof:
(i) was already known to it prior to disclosure by the disclosing party as
evidenced by written record or other proof;
(ii) was or becomes public knowledge through no fault of the receiving
party;
(iii)has been received from a third party who did not acquire it directly
or indirectly from the disclosing party;
(iv) is independently developed by the receiving party without reference to
any Confidential Information received from the disclosing party under
this Agreement; or
(v) is compelled to be disclosed in the course of litigation with a third
party, provided that the compelled party provides the disclosing party
with notice of such compulsion sufficiently in advance of disclosure
so as to provide the disclosing party with a reasonable time period to
seek a protective order.
Notwithstanding the above, the parties may disclose such Confidential
Information to their legal representatives and employees, and to consultants, to
the extent such disclosure is reasonably necessary to achieve the purposes of
this Agreement, obtaining an NDA for the Product for the Indication, and
provided such representatives, employees, and consultants are covered by
obligations of confidentiality with respect to such information no less
stringent than those set forth above.
ARTICLE VIII
Term and Termination
--------------------
8.01 Term. The term of this Agreement shall commence on the Effective Date
and shall continue for a period of 10 years thereafter, with automatic renewal
for successive 5 year terms for so long as Inpharmakon, Horizon, and their
respective Affiliates are in substantial compliance with the terms of this
Agreement, unless otherwise terminated earlier pursuant to this Article VIII.
8
9
[***] - CONFIDENTIAL TREATMENT REQUESTED
8.02 Termination for Material Breach. Either party may terminate this
Agreement in the event the other party materially breaches in the performance of
its obligations under this Agreement, and such breach continues for 90 days
after written notice specifying the breach was provided to the breaching party
by the non-breaching party. Any such termination shall become effective at the
end of such 90 day period unless the breaching party (or any other party on its
behalf) has cured any such breach prior to the expiration of the 90 day period.
A material breach is (i) the assertion of ownership rights by Inpharmakon in
violation of Section 2.02, (ii) the failure by either party to perform in a
timely manner the respective obligations and responsibilities of the parties
under Article III above, (iii) the failure by Horizon to pay the compensation
due under Article IV above, or (iv) the breach by either party of the
confidentiality provisions of Article VII above.
8.03 Bankruptcy. Either party may terminate this Agreement upon the filing
or institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of substantially all of the assets for the
benefit of creditors by the other party; provided, however, in the case of an
involuntary bankruptcy proceeding such right to terminate shall only become
effective if the party consents to the involuntary bankruptcy or such proceeding
is not dismissed within 90 days after the filing thereof.
8.04 Termination by Inpharmakon. Inpharmakon shall have the right to
terminate this Agreement on notice to Horizon in the event of:
(i) The failure of Horizon, within [***] after the Effective Date to
acquire or authorize a formulator to develop a workable once a day
formulation for the Product.
(ii) The failure of Horizon, within [***] after the Effective Date to
complete, in connection with the development of the Formulation, all
necessary in-vitro clinical studies and complete a clinical
bioavailability study in a small group of at least 8 patients,
provided that in the event that technical difficulties with such study
are encountered, such [***] period will be extended by [***] to
[***] if the bioavailability study was initiated within such [***]
period.
(iii)The failure of Horizon, within [***] after completing the clinical
bio-availability study on the Formulation under paragraph (ii) above,
to authorize or initiate the Clinical Trials.
(iv) The failure of Horizon to file the NDA within [***] after completion
of the Clinical Trials, including the full statistical analyses.
(v) The failure of the FDA within [***] of the filing date of the NDA for
the Product for the Indication, to approve the NDA unless the FDA is
9
10
[***] - CONFIDENTIAL TREATMENT REQUESTED
holding up approval pending agreement on labeling requirements for the
Formulation, in which case the period will be [***];
(vi) The failure of Horizon to make the First Commercial Sale within [***]
after receipt of the NDA approval for the Product for the Indication,
and to thereafter aggressively market and sell the Product for the
Indication.
Should Horizon have informed Inpharmakon in due time of serious reasons for
the delay in the achievement of the events under paragraphs (iii), (iv) or
(v) above, the parties shall negotiate in good faith an extension or
extensions of time for Horizon to complete the event delayed without
Inpharmakon exercising its termination rights provided that such serious
reasons do not delay the commercialization of the Product beyond [***]
after the Effective Date. Any waiver by Inpharmakon in one instance shall
not obligate Inpharmakon to grant any additional or other waivers of
Horizon's obligations.
ARTICLE IX
Consequences of Termination
---------------------------
9.01 Default of Horizon. If this Agreement is terminated for failure of
Horizon to pay any of the Article IV payments, or is terminated under Section
8.04(i) through (iv) and no default of Inpharmakon was the primary cause of the
default, Inpharmakon shall have the exclusive right to proceed with a NDA for
the Product for the Indication using the Formulation and the data from the
Clinical Trials as has been acquired or developed by Horizon at the date of
termination, and shall have the right to assume Horizon's rights to the same and
the NDA, if applicable, without cost to Inpharmakon or Inpharmakon Affiliates.
In that event Horizon shall release to Inpharmakon its rights to the Opportunity
Package, the Formulation, the related not publicly available information
provided by Inpharmakon or developed by or for Horizon, and registration data
related to the NDA for the Product for the Indication.
9.02 Failure to Commercialize. If this Agreement is terminated under
Section 8.04(vi) for failure to commercialize the Product for the Indication,
Inpharmakon shall have the exclusive option to purchase Horizon's rights to the
Formulation and the NDA for the Product for the Indication, if applicable, and
the exclusive right to use the data from the Clinical Trials, all for a price
equal to Horizon's booked costs incurred to obtain the same. In that event,
Inpharmakon shall have the right to proceed with a NDA for the Product for the
Indication by itself or through others.
9.03 No Fault Termination. If this Agreement is terminated under Section
8.04(v) Horizon shall have the right to proceed with an ANDA or NDA with any
formulation of [***] for any indication, including hypertension, without further
obligation to Inpharmakon, including but not limited to no obligation to pay
royalties on Net Sales of any and all formulations of the Product. In that event
Inpharmakon shall have an option to purchase Horizon's rights to the Formulation
and the data from the Clinical Trials at Horizon's booked costs incurred to
obtain the same, but only for the Indication.
10
11
[***] - CONFIDENTIAL TREATMENT REQUESTED
9.04 Conditions to Inpharmakon Rights. Inpharmakon's rights under Sections
9.01 and 9.02 above are conditioned upon the termination not arising primarily
from problems with the Opportunity Package or Inpharmakon's regulatory support
under Section 3.03ii) or iv). If the termination is as a result of such problems
Inpharmakon shall have no rights to the Formulation or the data from the
Clinical Trials. However, should Inpharmakon so request and have informed
Horizon in due time the reasons for the problems, the parties shall negotiate in
good faith an extension or extensions of time for Inpharmakon to repair or cure
the problems without Horizon exercising its termination rights hereunder. Any
waiver by Horizon in one instance shall not obligate Horizon to grant additional
or other waivers of Inpharmakon's obligations.
9.05 No Release of Prior Obligations. Termination of this Agreement for any
reason shall not release either party from any liability which, at the time of
such termination, has already accrued to the other party or which is
attributable to a period prior to such termination nor preclude either party
from pursuing all rights and remedies it may have under this Agreement or at law
or in equity with respect to any breach of the Agreement.
9.06 Survival of Terms. Articles IV, VI, VII, X, XI, XII and XIII, and
Sections 3.02 and 9.01 through 9.05 shall survive the expiration or termination
of this Agreement for any reason.
ARTICLE X
Representations & Warranties, Disclaimers & Indemnities
-------------------------------------------------------
10.01 Representations & Warranties.
(a) Horizon warrants and represents to Inpharmakon that it has or
prior to commercialization will have the right to manufacture, market and sell
[***], and that such manufacturing, marketing and sale will not infringe the
rights of any third parties.
(b) Inpharmakon warrants and represents that it has evaluated and, to
the best of its knowledge and belief, accurately reported all clinical
information, including safety and efficacy data, ft has included in the
Opportunity Package.
10.02 Inpharmakon Disclaimer. Inpharmakon specifically disclaims any
guarantee that the NDA for the Product for the Indication will be successful, in
whole or in part. Inpharmakon will evaluate and accurately report all clinical
information, including safety and efficacy data, it includes in the literature
package for the NDA, but expressly disclaims any responsibility to independently
verify such information for accuracy or completeness. Further, Inpharmakon
expressly disclaims any responsibility for independently verifying that such
clinical information pulled from publicly available or commercial sources does
not infringe third party proprietary rights. However, Inpharmakon has and will
exercise reasonable judgment in deciding whether or not such information should
be used in the NDA. Inpharmakon expressly disclaims responsibility for the
scientific methodologies, clinical protocols and results obtained and reported
in the published literature.
11
12
10.03 Indemnification. Horizon shall indemnify, defend and hold Inpharmakon
harmless from and against all product liability claims, actions, suits and other
proceedings, and related costs, including legal fees and expenses, liabilities,
damages and other expenses arising from (i) Horizon's use of the scientific
methodologies, clinical protocols and results referenced in Section 10.02 above
and (ii) the manufacture and sale of the Product. In addition, in the event of
any claims, actions, suits or other proceedings alleging that Horizon's use,
manufacture, marketing or sale of the Product infringes the rights of third
parties, Horizon shall indemnify, defend and hold Inpharmakon harmless from and
against all such claims, actions, suits or other proceedings, and related costs,
including legal fees and expenses, liabilities, damages, and other expenses
incurred by Inpharmakon arising therefrom. Horizon shall not be obligated to
indemnify Inpharmakon as aforesaid unless Inpharmakon promptly notifies Horizon
of the claim, action, suit, or other proceeding and Inpharmakon thereafter
cooperates with and assists Horizon, at Horizon's expense, in the defense of
such claim, action, suit or other proceeding.
ARTICLE XI
Notices
-------
All information, reports, notices and other communications under this
Agreement will be in writing. Such information, reports, notices and other
communications, and payments will be deemed given to a party when sent to such
party by certified or registered mail, return receipt requested, postage
prepaid; by hand; by facsimile, receipt confirmed; or by overnight courier which
provides confirmation of delivery, at the appropriate address set forth above.
Either party may change its address for the giving of notice by written notice
to the other party as set forth above.
ARTICLE XII
Arbitration
-----------
Any dispute arising out of the interpretation or performance of this
Agreement or the breach thereof, shall be submitted to arbitration in Chicago,
Illinois in accordance with the Commercial Rules of the American Arbitration
Association. The arbitration award shall be final and binding on the parties.
The arbitrators' fees shall be borne by the losing party. If both parties are
found liable, the arbitrators' fees shall be borne in proportion to the extent
to which each party is found liable. In the event either party is forced to take
legal action in order to enforce an arbitral award hereunder, the defending
party shall pay the claimant party's costs and expenses, including reasonable
attorney fees and expenses, incurred to enforce such arbitral award.
ARTICLE XIII
Miscellaneous
-------------
13.01 Independent Contractors. The relationship of the parties is that of
independent contractors. The parties are not deemed to be agents, partners or
joint venturers with the other for any purpose as a result of this Agreement or
the transactions contemplated thereby.
12
13
13.02 Amendment This Agreement may not be amended, supplemented, or
otherwise modified except by an instrument in writing signed by both parties.
13.03 Entire Agreement. This Agreement constitutes the entire agreement and
understanding of the parries relating to the subject matter of this Agreement.
It supersedes all previous communications, proposals, representations and
agreements (including the Confidential Disclosure Agreement dated June 25, 1998
and the Term Sheet dated October 13, 1998 between the parties), whether oral or
written, relating to the subject matter of this Agreement.
13.04 Severance. Should any provision of this Agreement be determined by a
court of competent jurisdiction to violate or contravene any applicable law or
policy, such provision shall be severed or modified to the extent necessary to
comply with the applicable law or policy, and such modified provision and the
remainder of the provisions hereof will continue in full force and effect.
13.05 Governing Law. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of Illinois, excluding any choice of law
rules which may direct the application of the law of any other jurisdiction.
13.06 Assignment. Neither party may assign its rights or obligations under
this Agreement without the prior written consent of the other.
13.07 Section Headings. All section headings are for reference purposes
only and shall not in any way affect the meaning or interpretation of this
Agreement.
13.08 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be an original, but all of which taken
together shall constitute one and the same agreement.
13
14
IN WITNESS WHEREOF, the duly authorized officers of the parties have
executed this Agreement as of the Effective Date.
INPHARMAKON CORPORATION
By:
-----------------------------------
Title:
--------------------------------
HORIZON PHARMACEUTICAL
CORPORATION
By:
-----------------------------------
Title:
--------------------------------
14
